| Literature DB >> 31260900 |
Jan Maciej Zaucha1, Stephane Chauvie2, Renata Zaucha3, Alberto Biggii4, Andrea Gallamini5.
Abstract
Classical Hodgkin Lymphoma is distinguished from other lymphomas by its peculiar biology and heterogeneous chemosensitivity. Most of the patients respond to the standard first-line treatment and are cured, however, in selected cases, the disease relapses or remains primarily refractory. Among predictive/prognostic factors 18FDG positron emission tomography (PET), fully integrated with computed tomography (PET/CT) proved to be extremely useful in identifying patients with poor prognosis at the time of diagnosis, during and at the end of treatment. The aim of this review is to present the current role of PET/CT in cHL at staging, interim and end of therapy assessment and its ability to guide treatment with a response- and risk-adapted strategy in clinical practice. Finally, quantitative PET measurement and the concurrent use of PET with selected biomarkers are discussed.Entities:
Keywords: ABVD; Hodgkin Lymphoma; Metabolic Tumor Volume; PET/CT; Radiomics; eBEACOPP
Mesh：
Year: 2019 PMID： 31260900 DOI： 10.1016/j.ctrv.2019.06.002
Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111